Summit Therapeutics Inc. Common Stock SMMT
$17.40
+1.58%
at last close
Market Cap$13.67 billion
P/E Ratio—
Div Yield—
Volume2.45M
52-Week Range
$12.07$30.98
Analyst Ratings
- Consensus
- Moderate Buy — 6 Buy · 7 Hold · 0 Sell (13 analysts)
- Avg. Price Target
- $26.99 (+55.1% upside)
Key Stats
- Today's Range
- $16.80 – $17.43
- 50-Day Range
- $12.07 – $17.43
- 52-Week Range
- $12.07 – $30.98
- Volume
- 2.45 million shs
- Average Volume
- 5.35 million shs
- Market Cap
- $13.67 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 21.69
- Price / Sales
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.02
About Summit Therapeutics Inc. Common Stock
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Related Stocks
Compare head-to-head: SMMT vs LLY·SMMT vs JNJ·SMMT vs ABBV·SMMT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.